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Abstract 
Smith-McCort dysplasia (SMC) is a rare autosomal recessive spondylo-epi-metaphyseal dysplasia 
with skeletal features identical to those of Dyggve-Melchior-Clausen syndrome (DMC) but with 
normal intelligence and no microcephaly. Although both syndromes were shown to result from 
mutations in the DYM gene, which encodes the Golgi protein DYMECLIN, a few SMC patients 
remained negative in DYM mutation screening. Recently, autozygosity mapping and exome 
sequencing in a large SMC family have allowed the identification of a missense mutation in 
RAB33B, another Golgi protein involved in retrograde transport of Golgi vesicles. Here, we report 
a novel RAB33B mutation in a second SMC case that leads to a marked reduction of the protein as 
shown by western blot and immunofluorescence. These data confirm the genetic heterogeneity of 
SMC dysplasia and highlight the role of Golgi transport in the pathogenesis of SMC and DMC 
syndromes. 
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Smith-McCort dysplasia (SMC; MIM# 607326) is a rare autosomal recessive skeletal dysplasia 
first described as an osteochondrodystrophy by R. Smith and J.J. McCort in 1958 (Smith and Mc, 
1958) and later highlighted by J. Spranger who proposed the term of Smith-McCort Dwarfism 
(Spranger, et al., 1976). SMC is characterized by a short trunk dwarfism with a barrel-shaped 
chest, rhizomelic limb shortening and specific radiological features including marked 
platyspondyly with double-humped end-plates, kyphoscoliosis, metaphyseal irregularities, laterally 
displaced capital femoral epiphyses and small pelvis with a lace-like appearance of iliac crests 
(Nakamura, et al., 1997). These clinical and radiological features are also common to Dyggve-
Melchior Clausen syndrome (DMC; MIM# 223800) and the two disorders are distinguished by the 
presence of mental retardation in DMC but a normal intelligence in SMC (Paupe, et al., 2004). A 
common gene responsible for both conditions, DYM, was identified in 2003 showing that SMC 
and DMC are allelic disorders and assigning SMC to the status of clinical variant of DMC with 
less severe outcome (El Ghouzzi, et al., 2003) (Cohn, et al., 2003). In the vast majority of DMC 
cases, identified mutations predict premature truncations of the DYM gene product and thus a 
complete loss-of-function of DYMECLIN (Paupe, et al., 2004) (Girisha, et al., 2008). By contrast, 
SMC was found to be associated with missense mutations thought to have a milder effect (Cohn, et 
al., 2003) (Santos, et al., 2009). However, DYM mutations have been reported in only three SMC 
families (Cohn, et al., 2003) (Santos, et al., 2009) among a total of twelve families reported so far 
(Smith and Mc, 1958) (Spranger, et al., 1976) (Koppers, 1979) (Nakamura, et al., 1997) (Bayrak, 
et al., 2005; Neumann, et al., 2006) (Gun, et al., 2012).  In addition, the absence of mutation in 
DYM in a well-characterized SMC patient had led us to hypothesize a possible genetic 
heterogeneity of the disease (Neumann, et al., 2006). In support of this hypothesis, Alshammari 
and colleagues have recently identified a missense mutation (p.K46Q) in a new gene, RAB33B, 
using autozygosity mapping and exome sequencing in a large consanguineous Saudi family 
(Alshammari, et al., 2012). RAB33B (MIM# 605950) belongs to the large Rab family of small 
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GTP-binding proteins that play important roles at defined steps of vesicular transport in protein 
secretion and the endocytosis pathway (Zheng, et al., 1998) (Barr and Lambright, 2010; Stenmark 
and Olkkonen, 2001). Like DYMECLIN, RAB33B localizes to the Golgi apparatus and is 
involved in Golgi homeostasis and trafficking (Osipovich, et al., 2008) (Dimitrov, et al., 2009) 
(Starr, et al., 2010). The recent implication of RAB33B in SMC prompted us to sequence this gene 
in our previously reported DYM-negative SMC patient (Neumann, et al., 2006). We report here the 
identification of a novel homozygous missense mutation in RAB33B in SMC dysplasia. 
 The patient is a 22-year old Turkish man who was diagnosed with SMC in 2006 
(Neumann, et al., 2006). He is the second child of healthy consanguineous parents and displays 
features typical of DMC/SMC with normal cognitive functions (Figure 1A). Height was 133cm, 
his head circumference was in the normal range. He had undergone genu valgum operation at the 
age of 12. Direct sequencing of the two exons of RAB33B from genomic DNA of the patient 
revealed a homozygous c.444T>A transversion in exon 2, predicting the substitution of the highly 
conserved asparagine by a lysine residue at codon 148 (p.N148K) (Figure 1B). Nucleotide 
numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation 
initiation codon in the reference sequence for human RAB33B (GenBank: AF350420.1), according 
to journal guidelines (http://www.hgvs.org/mutnomen). The initiation codon is codon 1. This 
substitution was found at the heterozygous state in the genomic DNA from both parents and absent 
in his healthy brother (Supp. Figure S1). It was absent as well from publicly available databases of 
known polymorphic variants, including dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/), 1000 
genome (http://www.1000genomes.org/) and Exome variant server 
(http://evs.gs.washington.edu/EVS/). In silico prediction of pathogenicity was also very high, with 
a PolyPhen-2 score of 1 (predicting a mutation “probably damaging” for the protein function) and 
a Sorting Intolerant From Tolerant (SIFT) score of 0.05 (which predicted an intolerant substitution 
for the protein). Moreover, it occurred in the G-4 GTPase domain of RAB33B (GenBank: 
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AAL83916.1) which is responsible for the specificity of the GTPase for the binding of guanine 
nucleotides through its 6th GTP/Mg2+ binding site and which is highly conserved both in RAB33B 
orthologues across species and in all RAB paralogues (Figure 2A and 2D, (Sanders, 1990)). This 
novel c.444T>A transversion has been submitted to the Leiden Open Variation Database 
(www.lovd.nl/RAB33B). 
 In order to evaluate the consequences of this novel mutation on RAB33B transcript and 
protein stability, we extracted mRNA and proteins from the patient’s fibroblasts. The c.444T>A 
substitution was also found at the mRNA level, indicating that the mutated mRNA was present 
(not shown). However, a marked reduction of the protein was observed in western blot even after 
loading a heavy amount of total proteins (60µg) (Figure 2B). This was also visible on fixed 
fibroblasts using the same anti-RAB33B antibody in immunofluorescence. The fluorescent signal 
was strongly decreased although not completely (Figure 2C). Moreover, co-labelling with an 
antibody against GIANTIN revealed a swollen and fragmented appearance of the Golgi apparatus 
in many cells. The loss of RAB33B fluorescence was much more pronounced in those cells, 
suggesting a correlation between the structure of the Golgi and the presence of RAB33B. 
However, this could be due also to a dilution effect in the swollen stacks. Finally, RAB33B was 
found present and normally localized in fibroblasts from a DMC patient bearing a well-
characterized splice mutation in DYMECLIN (c.194-1G>A) that was previously shown to result in 
skipping of exon 4 and premature termination of the protein (Figure 2B-C, (Neumann, et al., 
2006)). 
 This novel mutation is the second SMC mutation reported in RAB33B. Our findings 
confirm that SMC may be caused by a deficiency of either DYMECLIN or RAB33B and highlight 
that DMC and SMC both result from an altered Golgi trafficking. Results from this study and from 
Alshammari and colleagues (Alshammari, et al., 2012) show that specific missense mutations 
located in critical domains of RAB33B (Figure 2D) can cause a remarkable instability of the 
  6
protein. They also raise the question of whether the RAB33B gene would account exclusively for 
SMC, suggesting that mental retardation would be mainly associated with a complete loss-of-
function of the DYM gene. However, RAB33B analyses in additional cases of SMC and DMC 
syndromes are now required to answer this question. 
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Legends to Figures 
 
Figure 1. SMC phenotype and sequence chromatogram of the novel RAB33B mutation 
A. Photographs of the patient at the age of 22. Note the short trunk with barrel-shaped chest, 
pronounced curvature of the spine and normal head circumference. Written permission of the 
patient for reproduction of these photographs was obtained. 
B. Direct sequencing of RAB33B revealed a homozygous T>A transversion at position 444 of 
exon 2, predicting the substitution of the highly conserved asparagine by a lysine residue at codon 
148 (p.N148K). 
 
Figure 2. High conservation of the mutated asparagine residue during evolution and 
detection of the RAB33B protein 
A. Multiple alignment of the human G-4 GTPase domain (red frame) of human RAB33B 
(GenBank: AAL83916.1) with orthologues Rab33 proteins and paralogues Rab1A-3A proteins. 
Note the invariant conservation of the GNK motif that contains the asparagine residue (N in 
yellow) mutated in the SMC patient. 
B. Western blot analysis of RAB33B in human fibroblasts from a control (Ctl), a DMC patient 
with the c.194-1G>A mutation in the DYM gene previously shown to result in premature 
termination of DYMECLIN (DMC) and the SMC patient with the novel RAB33B mutation 
reported here (SMC). Note the almost complete absence of signal detected in the fibroblasts from 
the SMC case. (60µg total proteins loaded in each lane, the anti-RAB33B antibody was purchased 
from Frontier Bioscience and used at the concentration of 1µg/ml). 
C. Immunofluorescence detection of RAB33B in human fibroblasts from the control (Ctl) and 
same DMC and SMC patients along with DAPI and the Golgi marker GIANTIN. Note the strong 
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depletion of RAB33B in the fibroblasts from the SMC patient. (Anti-RAB33B and anti-GIANTIN 
antibodies from Abcam ab24586 were used at the concentration of 1µg/ml). 
D. Schematic representations (linear, left and three-dimensional, right) of the RAB33B protein 
showing the localization of the 5 GTPase domains (orange boxes) along with the 8 GTP/Mg2+ 
binding sites (green boxes) and the position of the two known mutations causing SMC dysplasia 
(p.K46Q (Alshammari, et al., 2012) and p.N148K (this study)). The three-dimensional 
representation of the RAB33B molecule was adapted from the crystallographic structure of the Rat 
protein (GenBank NP_00102414.1) available in Protein Data Bank Europe (PDBe, 
http://www.ebi.ac.uk/pdbe-srv/view/entry/1z06/secondary.html) and modified using the PyMol 
Software (version 1.5). Note that the two missense mutations are spatially very close to each other. 
 
Supplementary Figure S1. Sequence chromatogram of the healthy parents and brother 
The c.444T>A transversion in exon 2 of RAB33B was found at the heterozygous state in both 
parents but not in the healthy brother whose sequence was normal. 
 



